BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

Thermo Fisher Secures FDA Approval for Oncomine Dx Express Test as Companion Diagnostic for Dizal’s ZEGFROVY

Thermo Fisher Scientific, the world leader in serving science, announced the U.S. Food and Drug Administration (FDA) has approved the Oncomine&t...

July 04, 2025 | News

Lunit Partners with Microsoft to Scale AI-Powered Cancer Diagnostics Globally

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, announced a collaboration with Microsoft to accelerate the deliver...

July 03, 2025 | News

Dizal Secures FDA Approval for ZEGFROVY, the First Targeted Oral Therapy for EGFR Exon20ins NSCLC

ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins Approval follows the U....

July 03, 2025 | News

Taiwan Steps Into the Global Spotlight With a New Cancer Therapy

Traditional therapies often fall short in targeting these aggressive cancers with precision or safety. Can SOB100 improve drug delivery without the usual s...

July 02, 2025 | Report

AvenCell Secures Up to $40 Million AMED Grant to Advance Dual-Antigen Allogeneic CAR-T Therapy

AvenCell Japan, a wholly owned subsidiary of AvenCell Therapeutics, a private, clinical-stage biotechnology company developing best-in-class CAR-T therapie...

July 02, 2025 | News

Mabwell Grants Qilu Pharmaceutical Greater China Rights to Next-Generation Long-Acting G-CSF Albipagrastim Alfa

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its wholly-owned subsidiary T-mab has entered into an ag...

June 30, 2025 | News

QBiotics Reports 80% Response Rate in Phase IIa Soft Tissue Sarcoma Trial for Tigilanol Tiglate

Positive data from Stage 1 of the Phase IIa clinical trial (QB46C-H07) evaluating QBiotics' small molecule, tigilanol tiglate in 11 (10 evaluable) p...

June 26, 2025 | Report

Daiichi Sankyo and AstraZeneca’s DATROWAY Receives U.S. FDA Accelerated Approval for EGFR-Mutated Lung Cancer

Based on TROPION-Lung05 phase 2 trial results and supported by data from the TROPION-Lung01 phase 3 trial Second U.S. approval for Daiichi Sankyo and ...

June 24, 2025 | News

Harbour BioMed and Otsuka Ink $670M+ Global Deal to Advance Bispecific T-Cell Engager for Autoimmune Diseases

Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology,&nb...

June 23, 2025 | News

Sanyou Biopharmaceuticals and Medicovestor Forge Strategic Partnership to Advance First-in-Class Chemoimmunotherapy ADCs

Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D announced the signing ...

June 11, 2025 | News

Echosens and Boehringer Ingelheim Expand Partnership to Address the Growing Burden of MASH

As metabolic dysfunction-associated steatohepatitis (MASH) emerges as one of the most dangerous and underdiagnosed drivers of liver failure—affecting...

June 10, 2025 | News

QureBio Secures Nearly CNY 100 Million in Series C1 Funding Led by Efung Capital

Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 mil...

June 06, 2025 | News

Akeso’s Cadonilimab Secures NMPA Approval for First-Line Treatment of Cervical Cancer

Akeso, Inc. is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecif...

June 05, 2025 | News

Sanofi to Acquire Blueprint Medicines in $9.5 Billion Deal Expanding Rare Disease and Immunology Portfolio

Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a...

June 02, 2025 | News

Stay Connected